Hospira Expands Propofol and Lipsoyn Recall

March 31 recall expanded as a precaution to capture all affected lots
By Beth Gilbert
HealthDay Reporter

FRIDAY, June 11 (HealthDay News) -- Hospira has alerted health care providers that it is expanding its March 31 recall of Propofol Injectable Emulsion 1 percent and Liposyn (Intravenous Fat Emulsion) products that include Liposyn II 10 percent, Liposyn II 20 percent, Liposyn III 10 percent, Liposyn III 20 percent, and Liposyn III 30 percent, as some of the containers may contain sub-visible inert stainless steel particles.

The company issued the expanded recall because additional affected lots of propofol and Liposyn may have been distributed during a wider time frame and still be present in some customer inventories. The affected lots were distributed in the United States, Barbados, Canada, Chile, South Korea, Australia, Dominican Republic, Japan, Philippines, Puerto Rico, Uruguay, and the U.S. Virgin Islands.

Affected Liposyn lots were distributed between December 2008 and April 2010, and affected propofol lots were distributed between March 2008 and April 2010. The company has not received any reports of adverse events related to this issue.

"Hospira is undertaking this recall in consideration of the potential for safety issues if the products are administered to patients. Since these particulate contaminants do not dissolve in blood they could potentially act as emboli and impede blood flow," per a press release issued by Hospira. "Restriction in blood supply to tissues could lead to stroke, respiratory failure, kidney failure, liver failure, heart attack and/or death."

More Information

Copyright © 2010 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events